Jin, Xuan; Kim, Moo Hyun; Han, Ki Hoon; Hong, Soon Jun; Ahn, Jeong-Cheon; Sung, Jung-Hoon; Cho, Jin-Man; Lee, Han Cheol; Choi, So-Yeon; Lee, Kyounghoon; Kim, Woo-Shik; Rhee, Moo-Yong; Kim, Ju Han; Hong, Seung Pyo; Yoo, Byung Su; Cho, Eun Joo; Lee, Jae-Hwan; Kim, Pum-Joon; Park, Chang-Gyu; Hyon, Min Su; Shin, Jin Ho; Lee, Sang Hyun; Sung, Ki Chul; Hwang, Jinyong; Kwon, Kihwan; Chae, In-Ho; Seo, Jeong-Sook; Kim, Hyungseop; Lee, Hana; Cho, Yoonhwa; Kim, Hyo-Soo
Journal of clinical hypertension (Greenwich, Conn.)
2020Sep ; 20 ( 1 ) :.
PMID : 32937023
ÀúÀÚ »ó¼¼Á¤º¸
Jin, Xuan - Department of Cardiology, Dong-A University Hospital, Busan, Korea.
Kim, Moo Hyun - Department of Cardiology, Dong-A University Hospital, Busan, Korea.
Han, Ki Hoon - Division of Cardiology, Department of Internal Medicine, Asan Medical Center, Seoul,
Hong, Soon Jun - Division of Cardiology, Department of Cardiovascular Center, Korea University Anam
Ahn, Jeong-Cheon - Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
Sung, Jung-Hoon - Department of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam,
Cho, Jin-Man - Division of Cardiology, Department of Internal Medicine, Kyung Hee University
Lee, Han Cheol - Division of Cardiology, Department of Internal Medicine, Pusan National University
Choi, So-Yeon - Department of Cardiology, Ajou University School of Medicine, Suwon, Korea.
Lee, Kyounghoon - Division of Cardiology, Gachon University Gil Medical Center, Incheon, Korea.
Kim, Woo-Shik - Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
Rhee, Moo-Yong - Cardiovascular Center, Dongguk University Ilsan Hospital, Goyang, Korea.
Kim, Ju Han - Division of Cardiology, Department of Internal Medicine, Chonnam National University
Hong, Seung Pyo - Division of Cardiology, Daegu Catholic University Medical Center, Daegu, Korea.
Yoo, Byung Su - Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian
Cho, Eun Joo - Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary's
Lee, Jae-Hwan - Department of Cardiology in Internal Medicine, Chungnam National University
Kim, Pum-Joon - Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The
Park, Chang-Gyu - Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
Hyon, Min Su - Division of Cardiology, Department of Internal Medicine, Soonchunhyang University
Shin, Jin Ho - Department of Internal Medicine, Hanyang University College of Medicine, Seoul,
Lee, Sang Hyun - Division of Cardiology, Department of Internal Medicine, Pusan National University
Sung, Ki Chul - Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital,
Hwang, Jinyong - Department of Internal Medicine, College of Medicine, Gyeongsang National
Kwon, Kihwan - Department of Cardiology, Ewha Womans University College of Medicine, Seoul, Korea.
Chae, In-Ho - Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Seo, Jeong-Sook - Department of Internal Medicine, Busan Paik Hospital, Inje University College of
Kim, Hyungseop - Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan
Lee, Hana - Yuhan Research Institute, Yuhan Corporation, Yongin, Korea.
Cho, Yoonhwa - Yuhan Research Institute, Yuhan Corporation, Yongin, Korea.
Kim, Hyo-Soo - Division of Cardiology, Department of Internal Medicine, Seoul National University
ABSTRACT
Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the development and severity of cardiovascular disease. Treatment goals may be more effectively achieved if multiple disease factors are targeted with combination treatment. We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5?mg?+?rosuvastatin 20?mg, telmisartan 80?mg?+?rosuvastatin 20?mg, and telmisartan/amlodipine 80/5?mg. The primary efficacy variables were changes from baseline in mean sitting systolic blood pressure (MSSBP) between telmisartan/amlodipine 80/5?mg?+?rosuvastatin 20?mg and telmisartan 80?mg?+?rosuvastatin 20?mg at 8?weeks, and the percent changes from baseline in low-density lipoprotein (LDL) cholesterol between telmisartan/amlodipine 80/5?mg?+?rosuvastatin 20?mg and telmisartan/amlodipine 80/5?mg at 8?weeks. The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4?weeks and 8?weeks, as well as observed adverse events during follow-up. There were no significant differences between the three groups in demographic characteristics and no significant difference among the three groups in terms of baseline characteristics for the validity evaluation variables. The mean overall treatment compliance in the three groups was, respectively, 98.42%, 96.68%, and 98.12%, indicating strong compliance for all patients. The Least-Square (LS) mean (SE) for changes in MSSBP in the two (telmisartan/amlodipine 80/5?mg?+?rosuvastatin 20?mg and telmisartan 80?mg?+?rosuvastatin 20?mg) groups were -19.3 (2.68) mm?Hg and -6.69 (2.76) mm?Hg. The difference between the two groups was significant (-12.60 (2.77) mm?Hg, 95% CI -18.06 to -7.14, P?
keyword
amlodipine; dyslipidemia; hypertension; rosuvastatin; telmisartan
¸µÅ©